Intervention Protocol

Intranasal oxytocin for autism spectrum disorders (ASD)

  1. Lei Feng1,
  2. John CM Wong1,*,
  3. Rathi Mahendran1,
  4. Edwin SY Chan2,
  5. Michael D Spencer3

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 20 JAN 2014

DOI: 10.1002/14651858.CD010928

How to Cite

Feng L, Wong JCM, Mahendran R, Chan ESY, Spencer MD. Intranasal oxytocin for autism spectrum disorders (ASD) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010928. DOI: 10.1002/14651858.CD010928.

Author Information

  1. 1

    Yong Loo Lin School of Medicine, National University of Singapore, Department of Psychological Medicine, Singapore, Singapore

  2. 2

    Office of Clinical Sciences, Duke-NUS Graduate Medical School, Centre for Quantitative Medicine, Singapore, Singapore

  3. 3

    University of Cambridge, Autism Research Centre, Department of Psychiatry, Cambridge, England, UK

*John CM Wong, Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kend Ridge Road, Singapore, 119228, Singapore. pcmwcmj@nus.edu.sg.

Publication History

  1. Publication Status: New
  2. Published Online: 20 JAN 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy of intranasal oxytocin in improving social interaction and communication deficit, and other clinical outcomes in autism spectrum disorders (ASD), and to examine its safety.